Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report)'s stock price passed below its fifty day moving average during trading on Thursday after an insider sold shares in the company. The stock has a fifty day moving average of $522.74 and traded as low as $517.82. Vertex Pharmaceuticals shares last traded at $520.66, with a volume of 1,176,919 shares traded.
Specifically, Director Sangeeta N. Bhatia sold 271 shares of the company's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $547.86, for a total value of $148,470.06. Following the completion of the sale, the director directly owned 4,653 shares in the company, valued at approximately $2,549,192.58. This represents a 5.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the transaction, the director owned 1,109 shares in the company, valued at approximately $607,576.74. The trade was a 47.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In related news, EVP Charles Wagner, Jr. sold 15,286 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the transaction, the executive vice president directly owned 31,764 shares of the company's stock, valued at $17,402,542.68. This trade represents a 32.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Analyst Ratings Changes
A number of brokerages have commented on VRTX. Barclays boosted their target price on shares of Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an "overweight" rating in a report on Wednesday, November 4th. Royal Bank Of Canada raised their price target on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an "outperform" rating in a report on Tuesday, November 3rd. Rothschild & Co Redburn lifted their price objective on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Daiwa Securities Group boosted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Finally, Sanford C. Bernstein upgraded shares of Vertex Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $596.44.
Get Our Latest Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Trading Down 2.9%
The company has a 50 day moving average of $522.74 and a two-hundred day moving average of $485.01. The stock has a market capitalization of $132.01 billion, a PE ratio of 33.50, a P/E/G ratio of 2.84 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the business earned $4.80 earnings per share. The firm's revenue for the quarter was up 11.8% on a year-over-year basis. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.
Institutional Investors Weigh In On Vertex Pharmaceuticals
A number of institutional investors have recently modified their holdings of VRTX. PCM Encore LLC boosted its position in shares of Vertex Pharmaceuticals by 2.3% in the 3rd quarter. PCM Encore LLC now owns 2,177 shares of the pharmaceutical company's stock valued at $1,138,000 after purchasing an additional 49 shares during the period. Defiance ETFs LLC grew its stake in Vertex Pharmaceuticals by 16.5% during the 3rd quarter. Defiance ETFs LLC now owns 1,165 shares of the pharmaceutical company's stock worth $609,000 after buying an additional 165 shares during the last quarter. Kestra Advisory Services LLC increased its position in Vertex Pharmaceuticals by 46.1% during the third quarter. Kestra Advisory Services LLC now owns 22,981 shares of the pharmaceutical company's stock worth $12,015,000 after buying an additional 7,249 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $13,862,000. Finally, DGS Capital Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 23.5% in the third quarter. DGS Capital Management LLC now owns 1,501 shares of the pharmaceutical company's stock valued at $785,000 after buying an additional 286 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.